|Table of Contents|

Efficacy and safety of antibodies targeting PD-1/PD-L1 inhibitors versus chemotherapy in the treatment of advanced non-small cell lung cancer：A Meta-analysis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 22
Page:
3613-3619
Research Field:
Publishing date:

Info

Title:
Efficacy and safety of antibodies targeting PD-1/PD-L1 inhibitors versus chemotherapy in the treatment of advanced non-small cell lung cancer：A Meta-analysis
Author(s):
Qin Zemin; Fu Caihong; Zhang Feng; Lu Yaqiong; Guan Quanlin
Department of Oncological Surgery，the First Hospital of Lanzhou University，Gansu Lanzhou 730000，China.
Keywords:
PD-1/PD-L1; non-small cell lung cancer; chemotherapy; RCT
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2017.22.017
Abstract:
Objective:To evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer (NSCLC) by Meta-analysis.Methods：Retrieved from Cochrane Library，PubMed，EMBase，CNKI，Wanfang database，VIP database,RCT about PD-1/PD-L1 inhibitors versus chemotherapy for advanced NSCLC were included.Two reviewers independently screened literature,extracted data and assessed the risk of bias of the included studies.Results:Meta-analysis results indicated that the PD-1/PD-L1 inhibitors group (the trial group) was superior to the chemotherapy group (the control group) in objective response rate （ORR）［OR＝1.58，95％CI（1.27，1.97），P＜0.000 1］，overall response rate ［HR=0.68,95%CI(0.62,0.75),P＜0.000 01］，progression-free-survival response rate ［HR=0.79,95%CI(0.72,0.86),P＜0.000 01］.In the results of subgroup analysis,the HR for OS in NSCLC patients was ［HR=0.91，95%CI（0.76,1.11），P=0.35］ in patients with mutant EGFR and ［HR=0.67，95%CI（0.60,0.76），P＜0.000 01］ in patients with wild-type EGFR status.In terms of safety,any grade treatment-related adverse ［OR=0.32，95%CI（0.27，0.39），P＜0.000 01］ and grade 3 to 5 treatment-related adverse effect ［OR=0.18，95%CI（0.11，0.30)，P＜0.000 01］ in the trial group were lower than the control group.Conclusion：Compared with chemotherapy,the efficacy of PD-1/PD-L1 inhibitors regimen in the treatment of patients with advanced NSCLC was significantly higher than that of docetaxel-based chemotherapy,and the safety was superior to the latter.

References:

［1］ Jemal A,Bray F,Center MM,et al.Global cancer statistics［J］.CA Cancer J Clin,2011,61(2):69-90.
[2] Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012［J］.CA Cancer J Clin,2015,65(2):87-108.
[3]Brahmer J,Reckamp KL,Baas P,et al.Nivolumab versus docetaxel in advanced squamous cell non-small-cell lung cancer［J］.N Engl J Med,2015,373(2):123-135.
[4] Fossella F,Devore R,Kerr R,et al.Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.The TAX 320 Non-Small Cell Lung Cancer Study Group［J］.J Clin Oncol,2000,18:2354-2362.
[5] Yu YF，Chen ZW，Zhou Z，et al.A cost-effeciveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage Ⅲ b or Ⅳ non-small cell lung cancer in China［J］.Chemotherapy，2010,56（6）:472.
[6] Merelli B,Massi D,Cattaneo L,et al.Targeting the PD1/PD-L1 axis in melanoma:Biological rationale,clinical challenges and opportunities［J］.Crit Rev Oncol Hematol,2014,89(1):140-165.
[7] Freeman GJ,Long AJ,Iwai Y,et al.Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation［J］.J Exp Med,2000,192(7):1027-1034.
[8] Latchman Y,Wood CR,Chernova T,et al.PD-L2 is a second ligand for PD-1 and inhibits T cell activation［J］.Nat Immunol,2001,2(3):261-268.
[9] Topalian SL,Hodi FS,Brahmer JR,et al.Safety,activity,and immune correlates of anti-PD-1 antibody in cancer［J］.N Engl J Med,2012,366(26):2443-2454.
[10] Borghaei H,Paz-Ares L,Horn L,et al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer［J］.N Engl J Med,2015,373(17):1627-1639.
[11] Martin Reck,Rodriguez-Abreu D,Robinson AG,et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer［J］.N Engl J Med,2016,375:1823-1833.
[12] Herbst RS,Baas P,Kim DW,et al.Pembrolizumab versus docetaxel for previously treated,PD-L1-positive,advanced non-small-cell lung cancer (KEYNOTE-010):A randomised controlled trial［J］.Lancet,2016,387:1540-1550.
[13] Achim Rittmeyer,Fabrice Barlesi,Waterkamp D,et al.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK):A phase 3,open-label,multicentre randomised controlled trial［J］.N Engl J Med,2017,389:255-265.
[14] Rosell R,Carcereny E,Gervais R,et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC):A multicentre,open-label,randomized phase 3 trial［J］.Lancet Oncol,2012,13(3):239-246.
[15] Fukuoka M,Wu YL,Thongprasert S,et al.Biomarker analyses and final overall survival results from a phase III,randomized,open-label,first-line study of gefitinib versusb carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS)［J］.J Clin Oncol,2011,29(21):2866-2874.
[16] Yang JC,Hirsh V,Schuler M,et al.Symptom control and quality of life in LUX-Lung 3:A phase Ⅲ study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations［J］.J Clin Oncol,2013,31(27):3342-3350.
[17] Casaluce F,Sgambato A,Sacco PC,et al.Emerging drugs targeting PD-1 and PD-L1:Reality or hope［J］?Expert Opin Emerg Drugs,2014,19(4):557-569.
[18] Abdel-Rahman O,Helbling D,Schmidt J,et al.Treatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors.A systematic review and Meta-analysis［J］.J Clin Oncol,2016,28:127-138.
[19] Seiwert TY,Burtness B,Mehra R,et al.Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012):An open label,multicentre,phase 1b trial［J］.Lancet Oncol,2016,17:956-965.
[20] Fehrenbacher L,Spira A,Ballinger M,et al.Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):A multicentre,open-label,phase 2 randomised controlled trial［J］.Lancet,2016,387:1837-1846.
[21] Ribas A,Puzanov I,Dummer R,et al.Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002):A randomised,controlled,phase 2 trial［J］.Lancet Oncol,2015,16:908-918.
[22]Antonia SJ,Brahmer JR,Gettinger S,et al.Nivolumab (anti-PD-1.BMS-936558,ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC):Metastatic non-small cell lung cancer［J］.Int J Radiat Oncol Biol Phys,2014,90:S2.
[23] Shaw AT，Mehra R，Tan DSW，et al.Evaluation of ceritinib treated patients with anaplastic lymphoma kinase rearranged(ALK+) non-small cell lung cancer (NSCLC) and brain metastases in the ascend-1 study［J］.Ann Oncol，2014，25:455-456.
[24] Maemondo M，Inoue A，Kobayashi K，et al．Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR［J］.N Engl J Med，2010，362(25):2380-2388．

Memo

Memo:
甘肃省科技支撑计划项目（编号：1504FKCA084）；甘肃省卫生行业科研计划项目（编号：GSWST2013-16）
Last Update: 1900-01-01